The process includes encapsulating magnetic GZCIS/ZnS QDs within mesoporous silica, incorporating the chemotherapeutic agent epirubicin into the silica’s pores, layering with Au NPs, PEGylation, and conjugating with epithelial cell adhesion molecule (EpCAM) aptamers to specifically target colorectal cancer (CRC) cells. Here, EPCAM is linked to colorectal carcinoma.